GLP-1 safety and pharmacy verification
How to use GLP-1 medications safely, verify a compounding pharmacy, spot counterfeit or gray-market products, and understand what compounded GLP-1 status actually means. These pages prioritize safety over conversion.
Compounded GLP-1 medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing. Before starting any program, verify the dispensing pharmacy is named and state-licensed, confirm a real prescription pathway, and watch for the red flags covered below. Eligibility and treatment decisions belong to a licensed clinician.
Safety and verification guides
Is compounded GLP-1 medication safe?How to verify a compounding pharmacy503A vs 503B pharmacies explainedIs compounded GLP-1 legal in 2026?Semaglutide salt forms: the red flagVerify a compounding pharmacy: checklistHow to spot counterfeit GLP-1GLP-1 telehealth red flags
| Red flag | Why it matters |
|---|---|
| No named pharmacy | You can't verify state licensing or 503A/503B status before enrolling |
| No prescription required | Legitimate GLP-1 access always requires a clinician evaluation |
| Maintenance price under ~$200 (tirzepatide) | Below the API cost floor — signals bait-and-switch or non-legitimate sourcing |
| "FDA-approved compounded" claims | Compounded drugs are never FDA-approved; this is a false claim |
| Salt forms (semaglutide sodium/acetate) | Not the active ingredient in approved products; an FDA red flag |
Compounded GLP-1 medications occupy a narrow legal lane: after the 2025 shortage resolutions, routine copies of commercially available drugs are restricted, and legitimate compounding is limited to patient-specific clinical circumstances. A provider that ignores these boundaries, hides its pharmacy, or advertises guaranteed approval is worth avoiding regardless of price.
Reporting concerns
Report suspected counterfeit medication or adverse events to the FDA through MedWatch. If you experience a serious reaction — severe abdominal pain, repeated vomiting, difficulty breathing, facial or throat swelling — seek urgent medical care. This is educational information, not medical advice.
Sources
- FDA — human drug compounding and GLP-1 status. fda.gov/drugs/human-drug-compounding
- Pricing and program data captured from provider sites and major publishers (Forbes Health, U.S. News), July 2026. Full records: evidence ledger.
- Methodology: price-index and affordability methodology.
The numbers behind this page
What we do not claim in this page
Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.